Saturday 17 October 2026
Export ICU’s income statement to Excel — free account
SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million, up 814.1% from fiscal 2024. In the quarter to June 2026, revenue grew 82.0%, EPS grew 49.4% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.90
0.16
−5.23%
Follow ICU
SeaStar Medical Holding Corporation (ICU) P/E ratio
SeaStar Medical Holding Corporation has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 469× (November 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 469×
Ten-year median
0.0×
Current reading's percentile
95
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ICU SeaStar Medical Holding Corporation | n/m |
| RVLP RVL Pharmaceuticals PLC compare | n/m |
| LPCN Lipocine Inc. compare | n/m |
| CNSY Cerenome, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| KTTA Pasithea Therapeutics Corp. compare | n/m |
| BCDA BioCardia, Inc. compare | n/m |
| CLVSQ Clovis Oncology, Inc. compare | n/m |
| HIND Vyome Holdings, Inc. compare | 0.0× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)